Globus Medical (NYSE:GMED)

CAPS Rating: 5 out of 5

GMED News and Commentary

Caps

How do you think GMED will perform against the market?

Add Stock to CAPS Watchlist

All Players

43 Outperform
6 Underperform
 

All-Star Players

16 Outperform
1 Underperform
 

Wall Street

3 Outperform
1 Underperform
 

Top GMED Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFOpie (94.92)
Submitted May 26, 2017

Founder-led, cash rich, steady cash flows that it invests in reasonable acquisitions. The new Excelsius spinal solutions still awaiting FDA approval but expects to be more significant contributor over the next several years.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

GMED VS S&P 500 (SPY)

GMED Summary

Fools bearish on GMED are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about GMED.

Recs

0
Member Avatar TMFTypeoh (87.50) Submitted: 2/23/2018 7:02:35 AM : Outperform Start Price: $48.95 GMED Score: -3.20

Small, growing, profitable, new robotic surgery platform. Lots to like here.

Recs

0
Member Avatar TSprings11 (73.67) Submitted: 12/5/2017 3:50:43 PM : Outperform Start Price: $40.21 GMED Score: +14.84

Seems like a pretty under-the-radar stock for a 3.7B company. I interned at a health system on the business side and we bought one of their ExcelsiusGPS spinal surgery robots. Stock has outperformed more well known and RB rec. NuVaise. Has been gaining more attention from wall street with more buy ratings. Currently it is only 60% positive, but usually the buy ratings tend to follow each other so their could be upside. Robotic surgery is only going to be more popular, Globus looks like it could be a winner in that category. A stock I will continue to follow.

Recs

2
Member Avatar TMFOpie (94.92) Submitted: 5/26/2017 10:49:35 AM : Outperform Start Price: $31.11 GMED Score: +40.34

Founder-led, cash rich, steady cash flows that it invests in reasonable acquisitions. The new Excelsius spinal solutions still awaiting FDA approval but expects to be more significant contributor over the next several years.

Leaderboard

Find the members with the highest scoring picks in GMED.

Score Leader

pungocatfish

pungocatfish (< 20) Score: +249.76

The Score Leader is the player with the highest score across all their picks in GMED.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
pungocatfish < 20 1/3/2013 Outperform 3Y $10.94 +337.93% +88.17% +249.76 0 Comment
Squeege1981 < 20 12/24/2012 Outperform 3Y $10.96 +337.14% +92.81% +244.33 0 Comment
PerdidoBeacher 23.48 12/20/2012 Outperform 5Y $11.34 +322.49% +90.27% +232.22 0 Comment
Biotechnut < 20 12/3/2012 Outperform 5Y $12.05 +297.59% +93.83% +203.77 0 Comment
jayimsu 53.50 4/30/2013 Outperform 5Y $14.79 +223.94% +72.48% +151.45 0 Comment
Mostad08 63.95 5/22/2013 Outperform 5Y $15.76 +204.00% +64.14% +139.85 0 Comment
Santa007 < 20 8/15/2012 Outperform 3Y $14.32 +234.54% +95.00% +139.55 2 Comments
NewClueLess 20.28 11/11/2013 Outperform 5Y $18.52 +158.69% +55.10% +103.60 0 Comment
jsnms < 20 12/17/2013 Outperform 5Y $19.10 +150.84% +53.16% +97.68 0 Comment
sandvig 98.48 11/10/2016 Outperform 5Y $21.61 +121.70% +26.42% +95.28 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCanaccord < 20 1/22/2014 Outperform NS $23.09 +107.49% +48.90% +58.59 0 Comment
TrackWallachBeth 44.13 5/17/2013 Outperform NS $15.52 +208.70% +65.54% +143.16 0 Comment
TrackJimCramer 85.60 12/17/2012 Underperform 3W $11.61 +312.66% +91.08% -221.59 0 Comment
TrackPiperJaff 85.56 8/28/2012 Outperform NS $15.45 +210.10% +94.58% +115.52 0 Comment

Featured Broker Partners